Last reviewed · How we verify
Dydrogesterone M ( case 1 )
Dydrogesterone is a synthetic progestin that binds to progesterone receptors to support luteal phase function and maintain pregnancy.
Dydrogesterone is a synthetic progestin that binds to progesterone receptors to support luteal phase function and maintain pregnancy. Used for Threatened miscarriage, Recurrent miscarriage due to luteal insufficiency, Habitual abortion.
At a glance
| Generic name | Dydrogesterone M ( case 1 ) |
|---|---|
| Also known as | Dydrogesterone M |
| Sponsor | Trieu, Nguyen Thi, M.D. |
| Drug class | Progestin |
| Target | Progesterone receptor |
| Modality | Small molecule |
| Therapeutic area | Obstetrics/Gynecology |
| Phase | FDA-approved |
Mechanism of action
Dydrogesterone is a retro-isomer of norethisterone with selective progesterone receptor agonist activity. It mimics the effects of endogenous progesterone, promoting endometrial secretion and maintaining uterine quiescence during pregnancy. It is used to prevent miscarriage and support luteal insufficiency in women with threatened or recurrent pregnancy loss.
Approved indications
- Threatened miscarriage
- Recurrent miscarriage due to luteal insufficiency
- Habitual abortion
Common side effects
- Headache
- Dizziness
- Nausea
- Breast tenderness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Dydrogesterone M ( case 1 ) CI brief — competitive landscape report
- Dydrogesterone M ( case 1 ) updates RSS · CI watch RSS
- Trieu, Nguyen Thi, M.D. portfolio CI